Valuation: Waverley Pharma Inc.

Market Cap 1.35M 950K 831K 764K 712K 90.5M 1.37M 9.17M 3.56M 44.48M 3.57M 3.49M 153M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.75M 3.34M 2.92M 2.69M 2.5M 318M 4.82M 32.25M 12.54M 157M 12.55M 12.28M 539M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 month+150.00%
3 months+66.67%
6 months+25.00%
Current year+25.00%
1 month 0.02
Extreme 0.015
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.14
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member - 22/11/2023
Date Insider Type Main position Quantity % Market Cap.
24/06/24Other

Director

0 0%
18/08/21Other

Chairman

0 0%
18/08/21Option

Chairman

10,000,000 18.5185%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-37.50% 952K
+0.68%+5.92%+80.45%+137.78% 58.73B
+2.32%+5.03%+75.51%+94.88% 53.92B
+3.86%+6.93%-11.32%-9.53% 24.67B
+4.30%+7.95%+14.11%+437.83% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.29%+9.78%+44.62%-27.94% 17.61B
0.00%+20.78%+178.93%+360.74% 16.25B
+3.50%+1.97%+21.02%+191.95% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.58%+6.48%+49.17%+127.42% 24.21B
Weighted average by Cap. +2.44%+5.62%+59.06%+138.48%

Financials

2024 2025
Net sales 475K 335K 293K 269K 251K 31.87M 483K 3.23M 1.25M 15.66M 1.26M 1.23M 53.98M 1.35M 950K 831K 763K 712K 90.47M 1.37M 9.16M 3.56M 44.47M 3.57M 3.49M 153M
Net income -947K -667K -583K -536K -499K -63.49M -961K -6.43M -2.5M -31.21M -2.5M -2.45M -108M -499K -351K -307K -282K -263K -33.46M -507K -3.39M -1.32M -16.45M -1.32M -1.29M -56.68M
Net Debt 2.83M 1.99M 1.74M 1.6M 1.49M 190M 2.87M 19.22M 7.47M 93.27M 7.48M 7.32M 321M 3.4M 2.39M 2.09M 1.92M 1.79M 228M 3.45M 23.08M 8.97M 112M 8.98M 8.79M 386M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
29/06/26 CA$0.000000 - 100
25/06/26 CA$0.000000 -100.00% 200
  1. Stock Market
  2. Stocks
  3. WAVE Stock